Aficamten Phase 3 Data Disappoints: Shares Fall 6% on Modest Benefits and Safety Concerns
CYTK has more than doubled off its 52-week low of $35.22.
Summary
Cytokinetics' detailed Phase 3 ACACIA-HCM data for aficamten in non-obstructive HCM showed 53% of patients achieved meaningful improvement versus 13% on placebo, but the market focused on the drug's failure to improve heart structure or delay cardiovascular events. Safety concerns included a 10% rate of dangerous drops in heart pumping capacity and 12 heart failure events. Shares fell 6% as analysts questioned the modest benefit. The company plans a supplemental U.S. marketing application in Q4 2026, and Barclays forecasts over $5 billion in peak sales, but Bristol Myers' upcoming Camzyos study in nHCM adds competitive pressure. This follows the earlier Reuters report of the same data, but adds market reaction and safety details.
At the time of this announcement, CYTK was trading at $72.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1B. The 52-week trading range was $35.22 to $88.31. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.